1 / 34

First Do No Harm: Management of Atrial Septal Defect in Adult Patients

First Do No Harm: Management of Atrial Septal Defect in Adult Patients. Jimmy Klemis, MD Morbidity & Mortality Conference April 4, 2002. Case Presentation.

declan
Download Presentation

First Do No Harm: Management of Atrial Septal Defect in Adult Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. First Do No Harm: Management of Atrial Septal Defect in Adult Patients Jimmy Klemis, MD Morbidity & Mortality Conference April 4, 2002

  2. Case Presentation • 68 Female presents with 3rd admission in past 2yrs for “CHF” exacerbation. Notes progressive DOE, PND, Orthopnea, edema since prev admission 3 mos ago. Onset of sxs ~ 5-6 yrs ago. Denies any pleuritic CP, cough, F/C and compliant with medications/diet. • PMHx: 1) HTN 2) CHF • Meds: Lasix 40 Lisinopril 20 Dig .125

  3. Case Presentation • PE: HR 80 BP 140/80 • HNT: jvp 8cm • CV: fixed split S2, RV heave • Resp: basilar rales • Ext: 2+ edema • CXR pulm edema, CMG • ECHO – biatrial enlargement, RV enlargement, PA 40’s, no shunt on color flow

  4. Case Presentation • Cardiology consult for hx of prev ECHO showing “intra-atrial shunt” – given exam and progressive sxs, R/L heart cath done • R heart cath demonstrated O2 step up in high RA with demonstration of sinus venosus ASD and mod pulm HTN, PA systolic ~ 40 • Medical mgmt chosen by pt

  5. Historical Perspectives - ASD • 1513 – Leonardo da Vinci describes “perforating channel” in atrial septum • 1875 – Rokitansky first describes ASD • 1941 – Bedford et al describe clinical features • 1950’s – first successful open surgical repair • 1980’s- present - transcatheter approaches to repair

  6. ASD - Epidemiology • 1/3 of all Adult congenital heart disease • 2-3:1 female to male

  7. Embryologic Development Braunwauld 6th ed

  8. ASD - Anatomy Ostium Secundum -75% Ostium Primum - 15% Sinus Venosus - 10% Braunwauld 6th ed

  9. Associated conditions/ECG abnormalities • Ostium Secundum • MVP (10-20%) • IRBBB, RAD • Ostium Primum • MR/ cleft AMVL • LAD, 1st degree AVB 75% • Sinus Venosus • anomalous pulm venous drainage into RA or vena cavae • junctional/low atrial rhythm

  10. Physiologic Consequences • Shunt Flow • Size of defect • Relative compliance of ventricles • Relative resistance of pulmonary/systemic circulation • LR shunting results in diastolic overload of RV and increased pulmonary blood flow • RV dilatation/failure and rarely severe pulm HTN (Eisenmenger’s) may ensue over time ~5% • With age, deterioration chiefly due to 1 • decrease LV compliance, increased LR shunt • increase in atrial arrhythmias • pulm HTN develops, RV volume + pressure OL 1Perloff, NEJM 1995

  11. Clinical Symptoms • Often asymptomatic until 3-4th decade for moderate-large ASD, may present later in life for initially smaller ASD • Fatigue • DOE • Atrial arrhythmias • Paradoxical Embolus • Recurrent Pulmonary infections

  12. Physical Signs • S2 – wide/fixed splitting • RV/PA palpable impulse (if lg defect) • systolic ejection murmur 2nd L ICS • mid-diastolic TV rumble

  13. ECG

  14. ECHO • Subcostal view of Intraatrial Septum • Color Flow/ Contrast • Good for secundum, primum

  15. Catheterization • Oximetry • Shunt Ratio (Qp/Qs) Grossman, Cardiac Cath. 6th ed Ch 9

  16. Catheterization/Oximetry Grossman; Keane JF et al, Grossman Cardiac Cath.6th ed Chs 9,34

  17. Treatment • Medical : diuretics, ACEI, Aldactone • Repair • Consider when sxs, Qp:Qs>1.5 • Surgical • Mortality 1-3% in most series • PVR > 6-8 Woods Units - Contraindication • Interventional • Only for secundum defects • 94-96% success (Amplatzer)

  18. Percutaneous Devices used for Closure of ASD Amplatzer FDA approved, over 9,000 used with excellent results

  19. Early Studies of Prognosis/Natural History • 1941 Bedford describes clinical features 1 • 1957, 1970 Campbell 2,3 • untreated mortality • 25% Age 30, 75% age 50, 90% age 60 • noted that pattern of progressive disability began around 3rd decade and included dyspnea, cardiac failure, atrial fibrillation and pulmonary HTN • 1965 Markman4 • 67 pt 1943-1963, all survived to age 40 • 40% died/disabled by 5th decade • 90% older than 60 were severely disabled 1Bedford, et al. Br Heart J 1941; 2,3Campbell M, et al. Br Heart J 1957,1970 4 Markman P, et al. Q J Med 1965

  20. Early Studies of Prognosis/Natural History • 1968 Craig and Selzer 1 • 128 pt age 18-56, hemodynamic + clinical data • Generally agreed with earlier studies 1Craig RJ, Selzer A. Circulation 1968

  21. Purpose of study was to analyze long term survival among pt who underwent ASD repair - up to then data had been poorly documented

  22. Murphy JG, et al. • 123 pt Mayo Clinic 1956-1960 ASD repair • 62% female, mean age 26 (2-62) • 27-32 year followup • divided into groups according to age (<11, 12-24, 25-40, and >41)and presence of mod-sev pulm HTN (PA s>40) at time of cath • excluded primum ASD • 75% symptomatic, older pt more likely to be on med Rx (Dig, diuretic, Quinidine)

  23. Mortality followup at 27 years

  24. Survival Curves

  25. Murphy JG, et al - Summary • 28 deaths • 13 (48%) Cardiac death • 5 (19%) CVA (all in afib) • 6 (21%) Noncardiac (cancer, sepsis, resp fail) • Data on PVR available on only 42% of pt and was not included in statistical analysis • A stated purpose of study was to determine employability and insurability of these pt and was not meant to be a “guideline” • Led to consensus that repair <age 24 had nl mortality, between age 25-41 good survival but less than expected, and > age 41 had substantial increase in mortality • Pts advised to have ASD repair because untreated prognosis thought to be poor

  26. 82 pt (34 med 48 surgical) • 70% asymptomatic, Mean PAP sys 34/30 • 25 year followup • Outcome measures • Survival , symptoms, and complications

  27. Outcomes/Follow-up at 25 years

  28. Shah, et al. Conclusions • Earlier data showing high morbidity and reduced survival was based on a group of highly selected pt b/c florid clinical signs of ASD were needed before catheterization considered (pre ECHO) • In asymptomatic patients, ASD repair offered no benefit with regard to mortality, morbidity or progression to atrial arrhythmia • Limitations: uncontrolled study, advanced pulm HTN excluded (these pt do better with surgery), 22% of original pt lost to followup

  29. Children with sxs  ASD repair • Asymptomatic  close followup and repair when sxs/hemodynamic deterioration • Older pt >25, surgery may not benefit in terms of sxs/pulm HTN/mortality • Questioned benefit of routine surgical repair of older pt with ASD

  30. Sought to address issue of benefit/lack of benefit to ASD repair in middle aged-elderly pt • Retrospective, 179 pt with ASD dx > age 40 between 1966-1991 • 47% surgery 53 % medical • Mean followup of 8.9+-5.2 years • Women 70%

  31. Clinical / Baseline characteristics • PVR, Qp/Qs • Med Rx included Dig, diuretics • or nitrates • 94% of pt symptomatic

  32. Results 169% improvement in NYHA III/IV

  33. Konstantinides, et al - Summary • 31% reduction in mortality among symptomatic pt , age > 40 with surgical repair • Symptomatic improvement in NYHA functional class and less deterioration among surgically treated pt • No effect on atrial arrhythmias • First study to show benefit of surgery in older pt with ASD/ sxs • Limitations – retrospective, nonrandomized; excluded pt with CAD or severe MR (prev study by same author showed no benefit in unselected pt1) 1Konstantinides, et al. Circulation 1994

  34. Conclusions • Age < 25, sxs, significant ASD – Repair • Older age not contraindication and evidence supports mortality, symptomatic benefit for ASD repair in symptomatic pt with significant ASD

More Related